Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25925913 | 0.81 | MEN1 (0.50) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL24504568 | 0.76 | PTGS2 (0.39) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL25925732 | 0.74 | — | — | |
| SCHEMBL24504697 | 0.74 | KMT2A (0.49) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL12795330 | 0.74 | CYP1A2 (0.33) | MEN1KMT2ATSHRCYP1A2CYP2C9 | |
| SCHEMBL25928900 | 0.74 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL25925939 | 0.73 | MEN1 (0.31) | MEN1KMT2A | |
| SCHEMBL16802936 | 0.73 | PTGS1 (0.43) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL18631945 | 0.73 | PTGS1 (0.43) | MEN1KMT2AALDH1A1LMNATSHR | |
| SCHEMBL25925923 | 0.73 | L3MBTL1 (0.35) | MEN1KMT2AALDH1A1LMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | FUJIFILM CORPORATION (JP) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242523-A1 | COMPOUND, TAUTOMER OF COMPOUND OR SALT OF COMPOUND OR TAUTOMER, METHOD FOR PRODUCING SAME, COLORING COMPOSITION, DYEING METHOD, AND DYED ARTICLE | AR, MAPT, NR5A1 | MEN1 67/4885KMT2A 1814/4885ALDH1A1 580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.